Akebia Therapeutics Incorporated (NASDAQ:AKBA) Shorted Shares Increased 1.25% After Market Selling


The stock of Akebia Therapeutics Incorporated (NASDAQ:AKBA) registered an increase of 1.25% in short interest. AKBA’s total short interest was 2.18M shares in September as published by FINRA. Its up 1.25% from 2.15 million shares, reported previously. With 118,100 shares average volume, it will take short sellers 18 days to cover their AKBA’s short positions. The short interest to Akebia Therapeutics Incorporated’s float is 14.06%. About 36,830 shares traded hands. Akebia Therapeutics Inc (NASDAQ:AKBA) has risen 18.60% since February 8, 2016 and is uptrending. It has outperformed by 2.11% the S&P500.

Akebia Therapeutics, Inc. is a biopharmaceutical company. The company has a market cap of $328.57 million. The Firm is focused on the development of therapeutics based on hypoxia inducible factor biology, and the commercialization of these products for patients with serious medical needs. It currently has negative earnings. The Company’s segment is the business of developing and commercializing proprietary therapeutics based on HIF biology.

The institutional sentiment decreased to 1.21 in Q2 2016. Its down 0.29, from 1.5 in 2016Q1. The ratio dived, as 13 funds sold all Akebia Therapeutics Inc shares owned while 25 reduced positions. 12 funds bought stakes while 34 increased positions. They now own 19.00 million shares or 7.09% less from 20.45 million shares in 2016Q1.

Acuta Capital Partners Llc holds 2.16% of its portfolio in Akebia Therapeutics Inc for 600,000 shares. Nantahala Capital Management Llc owns 1.68 million shares or 1.36% of their US portfolio. Moreover, Venbio Select Advisor Llc has 1.03% invested in the company for 621,873 shares. The New York-based Perceptive Advisors Llc has invested 0.46% in the stock. P.A.W. Capital Corp, a Connecticut-based fund reported 40,000 shares.

Out of 4 analysts covering Akebia Therapeutics (NASDAQ:AKBA), 3 rate it a “Buy”, 0 “Sell”, while 1 “Hold”. This means 75% are positive. Akebia Therapeutics has been the topic of 6 analyst reports since December 7, 2015 according to StockzIntelligence Inc. H.C. Wainwright maintained the stock on March 15 with “Buy” rating.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Leave a Reply